Prostate-specific membrane antigen

Prostate

Volumn 32, Issue 2, 1997, Pages 140-148

  Fair, William R ^a   Israeli, Ron S ^a   Heston, Warren D W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Prostate specific membrane antigens; RSA; RT PCR

Indexed keywords

COMPLEMENTARY DNA; GLYCOPROTEIN; MEMBRANE ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ALTERNATIVE RNA SPLICING; ANTIGEN DETECTION; CARCINOMA CELL; CHROMOSOME 11; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REVIEW;

ALTERNATIVE SPLICING; ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 11; DNA, COMPLEMENTARY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0030981187     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970701)32:2<140::AID-PROS9>3.0.CO;2-Q     Document Type: Review

References (52)

1. Wingo PA, Tong T, Bolden D: Cancer Statistics, 1995. CA Cancer J Clin 45:8-30, 1995.
2. Coffey DS: Prostate cancer - an overview of an increasing dilemma. Cancer Suppl 71:880-886, 1993.
3. Carter HB, Partin AW, Oesterling JE, Weber JP, Epstein JI, Chan DW, Rock RC, Walsh PC: The use of prostate specific antigen in the management of patients with prostate cancer, the Johns Hopkins Experience. In Catalona WJ, Coffee DS, Karr JP (eds): "Clinical Aspects of Prostate Cancer." New York: Elsevier Scientific, 1989, pp 247-251.
4. Morgan WR, Zincke H, Rainwater LM, Myers RP, Klee GG: Prostate specific antigen levels after radical retro-pubic prostatectomy of adenocarcinoma of the prostate: Impact of adjunct treatments (hormonal and radiation). J Urol 145:319-323, 1991.
5. Epstein JI, Carmichael MJ, Pizov G, Walsh PC: Influence of capsular penetration on progression following radical prostatectomy: A study of 196 cases with long-term follow-up. J Urol 150:135, 1993.
6. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 7:927-936, 1987.
7. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818, 1983.
8. Wright GL, Haley C, Beckett ML, Schellhammer PF: Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1:18-28, 1995.
9. 90Y-CYT-356; a new prostatic cancer therapeutic agent. J Urol 147:361A, 1992 (abst).
10. Troyer JK, Fenk Q, Beckett ML, and Wright GL Jr: Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1:29-37, 1995.
11. Troyer JK, Feng Q, Beckett ML, Morningstar MM, Wright GL Jr: Molecular characterization of the 7E11-C5 prostate-tumor associated antigen. J Urol 149: 333A, 1993 (abst).
12. Feng Q, Beckett ML, Kaladas P, Gilman S, Wright GL Jr: Purification and biochemical characterization of the 7E11-C5 prostate carcinoma-associated antigen. Proc Am Assoc Cancer Res 32:239, 1991 (abst).
13. Israeli RS, Powell CT, Fair WR, Heston WDW: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53:227, 1993.
14. Troyer JK, Beckett ML, Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62:552, 1995.
15. Rochon YP, Horoszewicz JS, Boynton AL, Holmes EH, Barren RJ III, Erickson SJ, Kenny GM, Murphy GP: Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients. Prostate 25: 219-223, 1994.
16. Murphy G, Ragde H, Kenny G, Barren R III, Erickson S, Tjoa B, Boynton A, Holmes E, Gilbaugh J, Douglas T: Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res 15:1473-1479, 1995.
17. Murphy GP, Holmes EH, Boynton AL, Kenny GM, Ostenson RC, Erickson SJ, Barren RJ: Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement. Prostate 26:164-168, 1995.
18. von Heijne G: Transcending the impenetrable: How patients come to terms with membranes. BBA 947:307-333, 1988.
19. Parks GD, Lamb RA: Topology of eukaryotic type II membrane proteins: Importance of N-terminal positively charged residues flanking the hydrophobic domain. Cell 64:777-787, 1991.
20. Keer WP, Koslowski JM, Tsai YC, Lee C, McEwan RN, Grayhack JT: Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J Urol 143:381-385, 1990.
21. Rossi MC, Zetter BR: Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Natl Acad Sci USA 89:6197-6201, 1992.
22. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW: Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807, 1994.
23. Israeli RS, Rinker-Schaeffer CW, Powell CT, Isaacs JT, Fair WR, Heston WDW: Localization of the prostate specific membrane antigen (PSM) to the putative metastasis-suppressor region on human chromosome 11. Proc Am Assoc Cancer Res 35:271, 1994 (abst).
24. Henttu P, Liao S, Vihko P: Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but downregulate the prostatic cid phosphatase mRNA in the LNCaP cell line. Endocrinology 130:766-772, 1992.
25. Diamond SM, Fair WR, Wise GJ, Heston WDW: Modulation of prostate specific membrane antigen (PSM) expression in-vitro by cytokines and growth factors. J Urol 153:382A, 1995 (abst).
26. Montgomery BT, Young CYF, Bilhartz DC, Andrews TE, Prescott JL, Thompson NF, Tindall DJ: Hormonal regulation of prostate specific antigen glycoprotein in the human adenocarcinoma cell line, LNCaP. Prostate 21:63-73, 1992.
27. Mendelsohn J: Anti-EGF receptor monoclonal antibodies: Biological studies and potential clinical applications. Trans Am Clin Climatol Assoc 100:31-38, 1988.
28. Su SL, Huang IP, Fair WR, Powell CT, Heston WDW: Alternatively spliced variants of prostate-specific membrane antigen RNA: Ratio of expression as a potential measurement of progression. Cancer Res 55:1441-1443, 1995.
29. Israeli RS, Rinker-Schaeffer CW, Powell CT, Isaacs JT, Fair WR, Heston WDW: Localization of the prostate specific membrane antigen (PSM) to the putative metastasis suppressor region on human chromosome 11. J Urol 151:252A, 1994 (abst).
30. Rinker-Schaeffer CW, Hawkins AL, Su SL, Israeli RS, Griffin CA, Isaacs JT, Heston WDW: Localization and physical mapping of the prostate specific membrane antigen (PSM) gene to human chromosome 11. Genomics 30:105-108, 1995.
31. Leek J, Lench N, Maraj B, Bailey A, Carr IM, Andersen S, Cross J, Whelan P, MacLennan KA, Meredith DM, Markham AF: Prostate-specific membrane antigen: Evidence for the existence of a second related human gene. Br J Cancer 72:583-588, 1995.
32. Ichikawa T, Ichikawa Y, Dong J, Hawkins AL, Griffin CA, Isaacs WB, Oshimura M, Barrett JC, Isaacs JT: Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res 52:486-490, 1992.
33. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC: KAl1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268: 884-886, 1995.
34. Corr JG, Israeli RS, Huryk RF, Fair WR, Heston WDW: Prostate specific membrane antigen (PSM) expression in orthotopically implanted human prostate cancer cells in nude mice slows tumor growth and metastatic potential. J Urol 151:492A, 1994 (abst).
35. Carter RE, Feldman AR, Coyle JT: Prostate-specific membrane antigens is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 93:749-753, 1996.
36. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC: Immunorustochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 50:6423-6429, 1990.
37. Abdel-Nabi H, Wright GL, Gulfo JV, Petrylak DP, Neal CE, Texter JE, Begun FP, Tyson I, Heal A, Mitchell E, Purnell G, Harwood SJ: Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol 10:45-54, 1992.
38. 111Indium-labeled monoclonal antibody CYT-356. J Urol 152:1952-1955, 1994.
39. 111Indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 152:1490-1495, 1994.
40. Wu A, Ben-Ezra J, Colombero A: Detection of micrometastasis in breast cancer by the polymerase chain reaction. Lab Invest 62:109A, 1990.
41. Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood 82:1689-1694, 1993.
42. Miyajima Y, Kato K, Numata S, Kudo K, Horibe K: Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 75:2757-2761, 1995.
43. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG, Gomelia LG: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52:6110-6112, 1992.
44. Israeli RS, Miller WH Jr, Su SL, Powell CT, Fair WR, Samadi DS, Huryk RF, DeBlasio A, Edwards ET, Heston WDW: Sensitive nested RT-PCR detection of circulating prostatic tumor cells -Comparison of PSM and PSA-based assays. Cancer Res 54:6306-6310, 1994.
45. Israeli RS, Miller WH, Su SL, Samadi DS, Powell CT, DeBlasio A, Huryk R, Fair WR, Wise GJ, Heston WDW: Sensitive detection of prostatic hematogenous micrometastases using PSA and PSM-derived primers in the polymerase chain reaction. J Urol 153:573-577, 1995.
46. Lundwall A, Lilja H: Molecular cloning of a human prostate specific antigen cDNA. FEBS Lett 214:317, 1987.
47. Cama C, Olsson CA, Raffo AJ, Perlman H, Buttyan R, O'Toole K, McMahon D, Benson MC, Katz AE: Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 153:1373-1378, 1995.
48. Sokoloff M, Tso CL, Kaboo R, Nelson S, Dorey F, Figlin RA, Pang S, deKernion J, Belldegrun A: Quantitative polymerase chain reaction does not improve prostate cancer staging: A clinical-pathologic-molecular analysis of 121 patients. J Urol 156:1560-1566, 1996.
49. Fair WR, Israeli RS, Wang Y, Nawabi MD, Edwards ET, Heston WDW: Neoadjuvant androgen-deprivation therapy (ADT) prior to radical prostatectomy results in a significantly decreased incidence of residual micrometastatic disease as detected by nested RT-PCR with PSM primers. J Urol 153:391A, 1995.
50. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Candas B: Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy. Cancer Surv 23: 149-156, 1995.
51. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, Fair WR, Reuter VE: Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 18:979-991, 1994.
52. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMo) prostate cancer. The Lurpon depot neoadjuvant prostate cancer study group. J Urol 154:424-428, 1995.